NCT07532746 2026-04-16
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Kousai Bio Co., Ltd.
Phase 1 Not yet recruiting
Clinical Trials
22 trialsNCT07485504 2026-03-20
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Tcelltech Inc.
Phase 1 Not yet recruiting
NCT07428486 2026-02-23
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07423104 2026-02-20
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia
University of Rochester
Phase 2 Not yet recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT07342478 2026-01-16
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
Phase 3 Not yet recruiting
NCT07319793 2026-01-06
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Peking University People's Hospital
Phase NA Not yet recruiting
NCT07316907 2026-01-05
A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies
Affiliated Hospital of Jiangsu University
Phase 1 Not yet recruiting
NCT07306832 2025-12-29
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
AbbVie
Phase 1 Not yet recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT06987058 2025-09-24
ROVER-01
Ryvu Therapeutics SA
Phase 2 Not yet recruiting
NCT06281847 2025-09-18
RESOLVE AML001
Advesya SAS
Phase 1/2 Not yet recruiting
NCT07107204 2025-09-17
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
Phase 1/2 Not yet recruiting
NCT07175415 2025-09-16
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT07137637 2025-08-22
HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
Hangzhou Polymed Biopharmaceuticals, Inc.
Phase 1 Not yet recruiting
NCT05779930 2025-08-15
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
Phase EARLY_PHASE1 Not yet recruiting
NCT06837389 2025-02-20
Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT06754540 2025-01-17
Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT06641648 2024-10-15
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined with Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
Peking University First Hospital
Phase 1 Not yet recruiting
NCT06385808 2024-04-26
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Not yet recruiting
NCT06367114 2024-04-19
Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 2 Not yet recruiting
NCT06180499 2024-02-14
ILDTreg2
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Not yet recruiting